Kevin Latinis

5.4k total citations · 2 hit papers
21 papers, 4.0k citations indexed

About

Kevin Latinis is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Kevin Latinis has authored 21 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 8 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Kevin Latinis's work include CAR-T cell therapy research (6 papers), Systemic Lupus Erythematosus Research (6 papers) and T-cell and B-cell Immunology (6 papers). Kevin Latinis is often cited by papers focused on CAR-T cell therapy research (6 papers), Systemic Lupus Erythematosus Research (6 papers) and T-cell and B-cell Immunology (6 papers). Kevin Latinis collaborates with scholars based in United States, Mexico and United Kingdom. Kevin Latinis's co-authors include Gary A. Koretzky, Paul Brunetta, David Zhang, Joseph C. Shanahan, Lyse A. Norian, Daniel J. Wallace, Tammy O. Utset, Jim C. Oates, Jorge Sánchez‐Guerrero and C. Michael Neuwelt and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Kevin Latinis

21 papers receiving 3.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

2009 972 citations Joan T. Merrill, C. Michael Neuwelt et al. Arthritis & Rheumatism profile →
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

2012 972 citations Brad H. Rovin, Richard Furie et al. Arthritis & Rheumatism profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Kevin Latinis	2.1k	1.9k	1.3k	775	456	21	4.0k
Stefan Schönland	754 0.4×	444 0.2×	378 0.3×	5.9k 7.6×	1.4k 3.0×	222	7.2k
Michaela Liedtke	319 0.1×	581 0.3×	330 0.3×	2.5k 3.2×	294 0.6×	167	5.0k
Luís Teixeira	255 0.1×	585 0.3×	336 0.3×	604 0.8×	122 0.3×	93	3.3k
Jason D. Theis	444 0.2×	423 0.2×	116 0.1×	3.3k 4.2×	1.6k 3.5×	93	4.0k
Janet A. Gilbertson	661 0.3×	114 0.1×	241 0.2×	3.9k 5.0×	1.6k 3.6×	96	4.7k
Ashutosh Wechalekar	1.4k 0.7×	223 0.1×	524 0.4×	9.3k 12.0×	3.2k 7.0×	267	10.5k
David R. Stover	306 0.1×	401 0.2×	360 0.3×	1.4k 1.8×	22 0.0×	47	3.0k
Bryan L. Wharram	79 0.0×	552 0.3×	462 0.4×	1.1k 1.4×	1.4k 3.0×	33	3.0k
Nikolas von Bubnoff	683 0.3×	708 0.4×	132 0.1×	1.1k 1.5×	20 0.0×	138	4.1k
Steffen Koschmieder	729 0.3×	708 0.4×	58 0.0×	2.8k 3.6×	49 0.1×	222	5.2k

Countries citing papers authored by Kevin Latinis

Since Specialization

Citations

This map shows the geographic impact of Kevin Latinis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Latinis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Latinis more than expected).

Fields of papers citing papers by Kevin Latinis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Latinis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Latinis. The network helps show where Kevin Latinis may publish in the future.

Co-authorship network of co-authors of Kevin Latinis

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Latinis. A scholar is included among the top collaborators of Kevin Latinis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Latinis. Kevin Latinis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rovin, Brad H., Richard Furie, Kevin Latinis, et al.. (2012). Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis & Rheumatism. 64(4). 1215–1226. 972 indexed citations breakdown →

Stohl, William, Falk Hiepe, Kevin Latinis, et al.. (2012). Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 64(7). 2328–2337. 311 indexed citations

Chatham, Winn, Daniel J. Wallace, William Stohl, et al.. (2012). Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial. The Journal of Rheumatology. 39(8). 1632–1640. 66 indexed citations

Emery, P., Atul Deodhar, William F. C. Rigby, et al.. (2010). Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Annals of the Rheumatic Diseases. 69(9). 1629–1635. 253 indexed citations

Hamilton, Nancy A., et al.. (2010). The Mediating Role of Secular Coping Strategies in the Relationship Between Religious Appraisals and Adjustment to Chronic Pain: The Middle Road to Damascus. Social Indicators Research. 104(3). 407–425. 10 indexed citations

Merrill, Joan T., C. Michael Neuwelt, Daniel J. Wallace, et al.. (2009). Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatism. 62(1). 222–233. 972 indexed citations breakdown →

Mendoza, Fabian A., Carol M. Artlett, Nora Sandorfi, et al.. (2006). Description of 12 Cases of Nephrogenic Fibrosing Dermopathy and Review of the Literature. Seminars in Arthritis and Rheumatism. 35(4). 238–249. 192 indexed citations

Mendoza, Fabian A., et al.. (2006). Description of twelve cases of nephrogenic fibrosing dermopathy and review of the literature. The Medicine Forum. 22. 9 indexed citations

Cella, Marina, Keiko Fujikawa, Ilaria Tassi, et al.. (2004). Differential Requirements for Vav Proteins in DAP10- and ITAM-mediated NK Cell Cytotoxicity. The Journal of Experimental Medicine. 200(6). 817–823. 103 indexed citations

10.

Jiménez, Sergio A., Carol M. Artlett, Nora Sandorfi, et al.. (2004). Dialysis‐associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis & Rheumatism. 50(8). 2660–2666. 169 indexed citations

11.

Brasington, Richard, et al.. (2003). 14. Immunologic rheumatic disorders. Journal of Allergy and Clinical Immunology. 111(2). S593–S601. 59 indexed citations

12.

Norian, Lyse A., Kevin Latinis, Steve Eliason, et al.. (2000). The Regulation of CD95 (Fas) Ligand Expression in Primary T Cells: Induction of Promoter Activation in CD95LP-Luc Transgenic Mice. The Journal of Immunology. 164(9). 4471–4480. 16 indexed citations

13.

Faris, Mary, Kevin Latinis, Stephan J. Kempiak, Gary A. Koretzky, & André E. Nel. (1998). Stress-Induced Fas Ligand Expression in T Cells Is Mediated through a MEK Kinase 1-Regulated Response Element in the Fas Ligand Promoter. Molecular and Cellular Biology. 18(9). 5414–5424. 176 indexed citations

14.

Faris, Mary, Niels Kokot, Kevin Latinis, et al.. (1998). The c-Jun N-Terminal Kinase Cascade Plays a Role in Stress-Induced Apoptosis in Jurkat Cells by Up-Regulating Fas Ligand Expression. The Journal of Immunology. 160(1). 134–144. 218 indexed citations

15.

Peterson, Erik, Kevin Latinis, & Gary A. Koretzky. (1998). Molecular characterization of a CD95 signaling mutant. Arthritis & Rheumatism. 41(6). 1047–1053. 3 indexed citations

16.

Norian, Lyse A., Kevin Latinis, & Gary A. Koretzky. (1998). Cutting Edge: A Newly Identified Response Element in the CD95 Ligand Promoter Contributes to Optimal Inducibility in Activated T Lymphocytes. The Journal of Immunology. 161(3). 1078–1082. 26 indexed citations

17.

Norian, Lyse A., Kevin Latinis, & Gary A. Koretzky. (1998). A newly identified response element in the CD95 ligand promoter contributes to optimal inducibility in activated T lymphocytes.. PubMed. 161(3). 1078–82. 27 indexed citations

18.

Latinis, Kevin, Lyse A. Norian, Steve Eliason, & Gary A. Koretzky. (1997). Two NFAT Transcription Factor Binding Sites Participate in the Regulation of CD95 (Fas) Ligand Expression in Activated Human T Cells. Journal of Biological Chemistry. 272(50). 31427–31434. 197 indexed citations

19.

Latinis, Kevin, Laurie L. Carr, Erik Peterson, et al.. (1997). Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. The Journal of Immunology. 158(10). 4602–4611. 152 indexed citations

20.

Musci, Michael A., Kevin Latinis, & Gary A. Koretzky. (1997). Signaling Events in T Lymphocytes Leading to Cellular Activation or Programmed Cell Death. Clinical Immunology and Immunopathology. 83(3). 205–222. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact